Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2019 | Cost-effectiveness of 12-month VenG for CLL

Matthew Davids • 7 Dec 2019
ASH 2019
Chronic Lymphocytic Leukemia Leukemia Antibodies Obinutuzumab Venetoclax

Matthew Davids, MD, Dana-Farber Cancer Institute, Boston, MA, discusses a study estimating the cost-effectiveness of a 12-month fixed duration of venetoclax in combination with obinutuzumab (VenG) for the first-line treatment of chronic lymphocytic leukemia (CLL) in the United States. A 12-month fixed-duration treatment with VenG appears to be a cost-effective standard therapy for CLL patients. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.

More from Matthew Davids

Richter’s transformation: biology & ongoing trials in the field
Carsten Niemann et al. • 25 Mar 2024
1:53
CLL highlights from ASH 2023: the FLAIR study
Matthew Davids • 9 Dec 2023
2:15
CDK9 inhibition with voruciclib for treating AML and R/R B-cell NHL
Matthew Davids • 9 Dec 2023
1:21
Clinical characteristics and outcomes of the double refractory CLL/SLL patient population
Matthew Davids • 9 Dec 2023

Related Videos

1:17
An ongoing Phase I/II study of sonrotoclax + zanubrutinib in patients with treatment-naive CLL/SLL
Piers Patten • 28 Apr 2024
1:51
Should MRD eradication be the goal when treating every patient with CLL?
Dima El-Sharkawi • 28 Apr 2024
1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
The content of VJHemOnc is intended for healthcare professionals